Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.

MLA

van der Heijden, Lisa T., et al. “Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.” Journal of Clinical Pharmacology, vol. 64, no. 2, Feb. 2024, pp. 155–63. EBSCOhost, https://doi.org/10.1002/jcph.2362.

APA

van der Heijden, L. T., Ribbers, C. A., Vermunt, M. A. C., Pluim, D., Acda, M., Tibben, M., Rosing, H., Douma, J. A. J., Naipal, K., Bergman, A. M., Beijnen, J. H., Huitema, A. D. R., & Opdam, F. L. (2024). Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam. Journal of Clinical Pharmacology, 64(2), 155–163. https://doi.org/10.1002/jcph.2362

Chicago

van der Heijden, Lisa T., Claire A. Ribbers, Marit A.C. Vermunt, Dick Pluim, Manon Acda, Matthijs Tibben, Hilde Rosing, et al. 2024. “Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.” Journal of Clinical Pharmacology 64 (2): 155–63. doi:10.1002/jcph.2362.